| Author (y) | Country | Cases/controls | Study Type | Cancer(s) included | Mean age (SE)/age range | Timing of measurement | Measurement method | Cholesterol measure | Adjusted for |
| Inoue et al. (2009) [63] | Japan | 1263/26461 | Cohort | Colon/rectum and breast | 56.0 (8.2) | Fasting and nonfasting | NS | TGs, HDL | Adjusted for age, study area, smoking status, weekly ethanol intake, and total serum cholesterol | Iso et al. (2009) [64] | Japan | 1093/32275 | Cohort | Colorectal, prostate, leukemia, breast and cervical | 54.0 | Fasting and nonfasting | Enzymatic | TC | Age, BMI, pack year of smoking, ethanol intake, hypertension, diabetes, hyperlipidemia medication use, total vegetable intake, coffee intake, and public health centre | Kitahara et al. (2011) [65] | Korea | 44935/ 1144784 | Cohort | Oesophagus, colon/rectum, pancreas, prostate, kidney, and gallbladder | 30–95 | Fasting | NS | TC | Cigarette smoking, alcohol consumption, BMI, physical activity, hypertension, and fasting serum glucose | Mainous et al. (2005) [66] | USA | 203/3075 | Cohort | Cancer | 30+ | 12 hr fasting | NS | HDL | Age, gender, smoking status, and BMI | Melvin et al. (2012) [67] | Sweden | 6871/ 227603 | Cohort | Breast and ovarian | 25+ | Fasting and nonfasting | Enzymatic and immunoturbidimetric | TC, TGs, HDL, ApoA | Glucose, TGs, TC, age, parity fasting status, and SES | Chang et al. (2007) [68] | Turkey | 150/71 | Case | Breast | 49.2 (11.8) | 12 hr fasting | Enzymatic | TC, TGs, HDL, ApoA | HDL, apoA-I, apoB, ApoA-I/ApoB ratio, and VLDL | Furberg et al. (2004) [69] | Norway | 1287/ 27912 | Cohort | Breast | 43.6 (0.1) | Nonfasting | Enzymatic | HDL | Age, country of residence, parity, height, TC, recreational and occupation activity. Some models also included blood pressure, BMI, TGs, age at first birth, time since last meal, dietary energy, and fat intake | Ha et al. (2009) [70] | Korea | 714/169660 | Cohort | Breast | 55.9 (5.0) | Fasting | NS | TC | Age and BMI | Hayashi et al. (2012) [71] | Japan | 377/528 | Case | | >60 | Fasting | NS | TGs | Age, PSA level, prostatic volume, BMI, and TGs level | Kaye et al. (2002) [72] | USA | 158/725 | Case | Breast | 50–79 | NS | NS | TC | NS | Kim et al. (2009) [73] | Korea | 690/1380 | Case | Breast | 48.5 (7.6) | 8 hr fasting | Enzymatic | TGs, HDL | HDL, age, family history of breast cancer, age at menarche, age at the first full-term pregnancy, and total cholesterol | Lindemann et al. (2009) [74] | Norway | 100/31273 | Cohort | Endometrial | 56.1 | Nonfasting | Enzymatic | TC, TGs, HDL | Age, other lipids, and BMI | Cust et al. (2007) [75] | France | 284/546 | Case | Endometrial | 56.9 | Fasting and nonfasting | Enzymatic | TC, TGs, HDL | Age, laboratory batch, and case-control status | Seth et al. (2012) [76] | Sweden | 1144/ 224288 | Cohort | Endometrial | 25+ | Fasting and nonfasting | Enzymatic and immunoturbidimetric | TC, TGs, HDL, ApoA | Glucose, TC, TGs, age, parity, fasting status, and SES | Magura et al. (2008) [77] | USA | 312/319 | Case | Prostate | 50–74 | NS | NS | TC, TGs, HDL | Age, family history of prostate cancer, BMI, type 2 diabetes, smoking, and multivitamin use | Mondul et al. (2010) [78] | USA | 438/6378 | Cohort | Prostate | 35+ | NS | Enzymatic | TC | Age, race, BMI, education level, smoking status, intake of meat, dairy, tomato products and alcohol, family history of prostate cancer, PSA screening, and use of diabetes medications | Mondul et al. (2011) [79] | USA | 2041/27052 | Cohort | Prostate | 50–69 | NS | Enzymatic | TC, HDL | Age, serum α-tocopherol, family history of PCA, education level, and urban residence | Platz et al. (2009) [80] | USA | 1251/4335 | Cohort | Prostate | 63.1 | Nonfasting | Enzymatic | TC | Age, race, first-degree family history of prostate cancer, BMI, self-reported diabetes mellitus, regular aspirin use, and history of myocardial infarction | Van Hemelrijck et al. (2011) [81] | Sweden | 2008/65719 | Cohort | Prostate | 35+ | Fasting and nonfasting | Enzymatic and immunoturbidimetric | HDL, ApoA | Age, glucose, TGs, and TC, fasting status, and SES. | Van Hemelrijck et al. (2011) [82] | Sweden | 5112/ 195548 | Cohort | Prostate | 45–75 | Fasting and nonfasting | Enzymatic and immunoturbidimetric | TC, TGs | Glucose and/or TGs and/or TC, SES, fasting status, and time between measurements and entry | Bravi et al. (2005) [83] | Italy | 1294/1451 | Case | Prostate | 46–74 | NS | NS | TC | Age, centre, education, BMI, physical activity, tobacco smoking, alcohol consumption, and family history of prostate cancer | Tsushima et al. (2005) [84] | USA | 1004/21255 | Cohort | Colorectal | NS | Nonfasting | NS | TGs | Age, elapsed time since last calorific intake and 50 g glucose load, BMI, heart rate, cigarette smoking history, alcohol intake, and 24 h intake of total calories | Van Duijnhoven et al. (2011) [85] | W. Europe | 939/939 | Cohort | Colorectal | 35–70 | Fasting and nonfasting | Enzymatic | TC, TGs, HDL, ApoA | Age, gender, BMI, other lipids, height, weight, smoking habits, physical activity, education, consumption of fruit, vegetables, meat, fish, and alcohol, intake of fibre, energy from fat, and energy from nonfat | Chung et al. (2006) [86] | Korea | 105/105 | Case | Colorectal | 58.6 (8.3) | 12 hr fasting | Enzymatic | TC, TGs | Age, gender, BMI, glucose, triglycerides, and total cholesterol | Van Hemelrijck et al. (2012) [87] | Sweden | 156/82391 | Cohort | Kidney | 20+ | Fasting and nonfasting | Enzymatic and immunoturbidimetric | TC, TGs, HDL, ApoA | Age, gender, glucose, TGs and TC, creatinine levels, fasting status, and SES | Andreotti et al. (2008) [88] | USA | 264/1839 | Case | Biliary | 34–75 | Overnight fasting | NS | TC, TGs, HDL, ApoA | Age, gender, BMI, waist-to-hip ratio, cigarette smoking, alcohol drinking, hypertension, diabetes, and gallstone status | Asano et al. (2008) [89] | Japan | 97/2507 | Cohort | Gastric | 59.2 (0.3) | Fasting and nonfasting | Enzymatic | TC | Age and gender |
|
|